Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 9/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785853 | 0.89 | RORC (0.40) | RORCNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL784810 | 0.89 | RORC (0.40) | RORCNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL803509 | 0.88 | RORC (0.39) | RORCNPC1RAB9ASMN1; SMN2MAPK14 | |
| SCHEMBL803203 | 0.86 | MGLL (0.38) | MAPK14SLC6A2SLC6A4SLC6A3ACHE | |
| SCHEMBL13131593 | 0.84 | HPGD (0.46) | NPC1RAB9ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL803190 | 0.84 | HPGD (0.46) | NPC1RAB9ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL803727 | 0.82 | HPGD (0.40) | NPC1RAB9AMAPK14SLC6A2SLC6A4 | |
| SCHEMBL803553 | 0.82 | TRPM8 (0.39) | SMN1; SMN2MAPK14SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2818207 | 0.80 | TAS1R3 (0.50) | NPC1RAB9ASMN1; SMN2SLC6A2SLC6A4 | |
| SCHEMBL803178 | 0.80 | TAS1R3 (0.50) | NPC1RAB9ASMN1; SMN2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | RORC 4667/4885NPC1 2033/4885RAB9A 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.